Data Quality and Integrity: From Clinical Monitoring to Marketing Approval
|
|
- Clifford Howard
- 6 years ago
- Views:
Transcription
1 Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November
2 Objectives Identify the importance of accuracy, completeness and validity of data collected during a clinical development program Plan for a clinical study report used for marketing approval Discuss the importance of monitors and investigational site personnel in increasing the quality of data required for marketing approval 2
3 Outline Overview Marketing application Data collection and monitoring Clinical study report (CSR) 3
4 Start at the end! Keep it simple! Maintain consistency! 4
5 Start at the end The primary goal in product development is to bring new compounds to market that can either treat previously untreatable diseases or offer improved benefits to patients, when compared to existing drugs 5
6 Start Line Hypothesis/ Study design and planned analysis Monitor s Pit Stop Investigator 1 Investigator 2 Investigator 3 Finish Line Clinical study report / Marketing Application Investigator 4 Monitor s Pit Stop 6
7 What is needed to obtain a marketing approval? Regulatory authorities thoroughly review a marketing submission to evaluate the data submitted for a product. The product has to demonstrate efficacy with acceptable safety Results and conclusions of studies -CSRs This relies on data quality and integrity Exploratory analyses on raw data Regulatory Authority audits at sites 7
8 What should be done to meet the requirements of data quality? Actions must be taken in the earliest clinical stages Sponsors are responsible for developing appropriate study designs and planned analyses 8
9 What should be done to meet the requirements of data quality? (2) Investigators, site personnel and monitors are the frontline players who ensure protocol compliance and provide clean clinical data which, in turn, will provide quality efficacy and safety analyses in CSRs that ultimately supports marketing approval 9
10 How should these actions be done? There is no universal way, since each clinical development program is unique There are universal guidelines Applicable laws Directives Guidelines ICH E6 Good Clinical Practices (GCPs) ICH E3 Structure and content of CSRs Standard operating procedures 10
11 Definition of GCPs «An international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.» 11
12 GCPs why do we need them? To protect the rights, integrity and confidentiality of subjects To ensure that all data collected and reported during the trial are credible and accurate 12
13 Principles of GCPs Data collection (1) 1. Clinical trials should be scientifically sound, and described in a clear, detailed protocol 2. Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s) 3. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.
14 Principles of GCPs Data collection (2) 4. Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol 5. Systems with procedures that assure the quality of every aspect of the trial should be implemented.
15 Marketing application 15
16 Marketing application Nonclinical data Chemistry, manufacturing and controls (CMC) data Clinical data Overview and summaries of integrated efficacy and safety data - all clinical studies conducted with the product during the clinical development program CSRs 16
17 Marketing application (2) Labeling Defines appropriate patient population for treatment Provides adequate information to enable safe and effective use 17
18 Regulatory marketing application CTD Quality Overall Summary (2.3) 1 Regional Administrative Forms LABELING Module 2 CTD Table of Contents (2.1) CTD Introduction (2.2) Nonclinical Overview (2.4) Nonclinical Written and Tabulated Summary (2.6) Clinical Overview (2.5) Clinical Written Summary (2.7) Module 3 Module 4 Module 5 Labeling Overall Summary Detailed Summaries Tabulated Summaries Quality Nonclinical Study Reports Clinical Study Reports Reports/Data Q S E Q = Quality/Chemistry,CMC S = Safety/Nonclinical E = Efficacy/Clinical 18
19 Marketing application Clinical review (1) The role of the product in the existing treatment standard of care for the indication Efficacy data Study design Choice of endpoints, study population Choice of control, adequacy of blinding Appropriateness of statistical analyses Contribution of sponsors is crucial 19
20 Marketing application Clinical review (2) Study design Per GCPs Section 6.4: «The scientific integrity of the trial and the credibility of the data from the trial depend substantially on the trial design» The protocol design and planned analyses and ultimately case report forms (CRFs) design have important influences on data quality. Prospectively identify the critical data Simplify data collection Contribution of sponsors is crucial 20
21 Marketing application Clinical review (3) Aspects of the conduct of the study which are deemed critical to conclusions Protocol compliance Eligibility, blinding, randomization, treatment, assessments, concomitant medications Contribution of monitors and investigational site personnel is crucial 21
22 Marketing application Clinical review (4) Safety data Extent of safety testing, size of the safety database Duration of exposure Common adverse events Deaths, other serious adverse events and adverse events that led to discontinuation Narratives, listings, CRFs Contribution of sponsors, monitors and investigational site personnel is crucial 22
23 Marketing application Clinical review (5) Listings Tables Data Consistency Labeling Summaries 23
24 Marketing application Lessons learned (1) Complete case report forms are submitted for: Deaths Other serious adverse events Other significant adverse events (e.g., adverse events leading to discontinuation) Adequate completion and monitoring are important since authorities require the case report forms to be part of the submission! 24
25 Marketing application Lessons learned (2) Data uniformity Laboratory testing units For same tests, various units could be used in different countries/sites 25
26 Marketing application Lessons learned (2) Adverse events causality definitely, probably, possibly, suspected, likely etc. Be consistent and keep it simple! 26
27 Data collection and monitoring 27
28 Clinical data flow - data collection and monitoring 28
29 Purpose of monitoring Assures the integrity of data generated Assures appropriate study conduct in accordance with GCP To ensure the validity and accuracy of the data, sponsors periodically send monitors to study sites to verify that subjects are treated according to the study protocol and that the information is reported accurately. 29
30 Protocol compliance and data validity Appropriately trained investigators and site personnel are critical to ensure the protocol is followed correctly and that CRFs are properly completed Study monitors check on the progress and quality of performance of the study by reviewing CRFs and other study records to ensure that the documentation is complete 30
31 What can the sponsor do to help obtain clean data? Ensure all study documents (protocol, lab manual, CRF, etc..) are clear and contain enough detail Will minimize ambiguity on the site s end and make the execution of the study easier CRF completion guidelines Will reduce the number of queries Ensure the monitors are appropriately trained
32 What can a monitor do to obtain cleaner data? (1) Training does not end at the site initiation visit; it is done throughout the study New site personnel and every time errors/omissions are noted in the CRF Understand what needs to be captured Review tools available (e.g., CRF completion guideline, Q&A log and meeting minutes) Keep track of individual CRF entry decisions 32
33 What can a monitor do to obtain cleaner data? (2) Ensure consistency: between sites with respect to CRF entry and DCR resolution between SAE reports and AE CRF pages between the same data collected on more than one CRF page Provide instruction to site if new DCRs should be expected on-site after the site termination visit Maintain a good rapport with the study coordinator! 33
34 Data collection is conducted according to GCPs Consequences of noncompliance Suspension or cancellation of trial and seizure of investigational product Market approval of investigational product declined Prosecution under penalties defined in each country law 34
35 Data collection and monitoring Lessons learned (1) Documentation is the key for auditors to be able to reconstruct the study. Document everything! If it isn t documented it wasn t done! 35
36 Data collection and monitoring Lessons learned (2) Safety assessments AE Causality It is often the study coordinator that is entering the AE causality in the CRF and it is rarely documented in the source documents A good monitor will ensure that the investigator has been the one to do the final determination It is important to remember that it is the investigator s responsibility to assign each AE causality, not the study coordinator nor the sponsor. 36
37 Data collection and monitoring Lessons learned (3) When discussed with monitors, they all say that they became better monitors when they helped reviewing data listings and assisted authoring CSRs Look at things from a different perspective! 37
38 Clinical study report 38
39 Clinical data flow Clinical study report 39
40 Clinical study report Guidelines ICH Harmonised Tripartite Guideline E3, Structure and Content of Clinical Study Reports : Single core clinical study report acceptable to all regulatory authorities of the ICH regions Additional modules/appendices meet regional regulatory requirements 40
41 Clinical study reports Advantages of the standard format Familiarity for all reviewers Consistency for marketing application in multiple ICH regions 41
42 Clinical study report Structure Fully integrated clinical and statistical report Report body Sections 1.0 to 15.0 Appendices Section
43 Clinical study report Organization (1) Section 1.0: Title page Section 2.0: Synopsis Section 3.0: Table of contents Section 4.0: List of abbreviations, definitions of terms Section 5.0: Ethics Section 6.0: Investigators and study administrative structure Section 7.0: Introduction Section 8.0: Study objectives 43
44 Clinical study report Organization (2) Section 9.0: Investigational plan Section 10.0: Study subjects Section 11.0: Efficacy evaluation Section 12.0: Safety evaluation Section 13.0: Discussion and overall conclusions Section 14.0: Tables, figures, and graphs referred to but not included in the text Section 15.0: Reference list Section 16.0: Appendices 44
45 Clinical study report Content Provide adequate detail to allow regulatory authorities to replicate critical analyses Clear explanation of how critical study design features were chosen Clear explanation of the planned and actual methods, and conduct of the study Adequate individual subject data and details of analytical methods (data listings) 45
46 Clinical study report High quality document Complete Design, methods, conduct, deviations Summary and individual subject data Efficacy and safety evaluations and conclusions Well organized, free of ambiguity or inconsistencies Accurate representation of the clinical data 46
47 Clinical study report Tables and figures Essential results for the following should be presented and summarized in text and repeated in Section 14.0: Demographics Efficacy Safety Pharmacokinetics (if applicable) Cross reference to text, and supporting tables, figures, and data listings in Appendices. 47
48 Clinical study report Typical timelines 2 months is a reasonable period to finalize a CSR but Can be accelerated depending on sponsor needs! 48
49 Clinical study report Study specific documents (1) Final protocol and amendments Statistical analysis plan and amendments, if available CRF Investigator s Brochure Information on waivers and protocol deviations Study procedures manual, if available Central lab manuals with reference ranges Investigational product information Study s regulatory history 49
50 Clinical study report Study specific documents (2) Site visit reports Compliance Issues Adverse events Serious adverse event reports SAE reports/medwatch forms Site narratives 50
51 Clinical study report Study specific documents (3) Site correspondence related to deviations/ exceptions Inclusion / exclusion exception request Deviation request Notes to file Previous example of CSR from sponsor (if available) 51
52 Clinical study report Lessons learned (1) Do not wait for the study to finish to start the clinical study report Begin authoring as soon as the protocol and statistical analysis plan are finalized! 52
53 Clinical study report Lessons learned (2) The CSR data presentation should be based on the efficacy and safety summaries required for the marketing application If a sponsor thinks far enough ahead to plan for marketing application from the beginning, they are more likely to successfully cross the finish line! 53
54 Clinical study report Lessons learned (3) Ensure that the tables and listings have undergone a quality control review and are considered final before beginning to author the efficacy and safety evaluation sections of the CSR Otherwise you may be in for plenty of unwanted surprises and lots of re-writing! 54
55 Clinical study report Lessons learned (4) Protocol deviations Usually not in the CRF but presented in monitoring reports Determine what information is to be included and how detailed it will be Plan ahead! It is more efficient to build a tool at the planning and initiation stages than try to retrieve the information at the end when time is precious 55
56 Conclusion Obtaining high-quality data in the most efficient way is a question of team effort! Interaction and contribution Sponsors, investigational sites and regulatory authorities Processes Monitoring Auditing Tools Guidance documents Study documents Quality control plan 56
57 Start Line Hypothesis/ Study design and planned analysis Monitor s Pit Stop Investigator 1 Investigator 2 Investigator 3 Finish Line Clinical study report / Marketing Application Investigator 4 Monitor s Pit Stop 57
58 Rational study design and analyses Data standardization / simplification Sponsor Monitor Investigator/site Careful monitoring Protocol compliance Adequate completion of source documents / CRF Adequate safety reporting Well- organized and high quality CSR and marketing application Inspection preparation 58
59 Start at the end! Keep it simple! Maintain consistency! 59
60 Questions? 60
GCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationEnsuring Quality of Regulatory Clinical Documents
Ensuring Quality of Regulatory Clinical Documents Henry Li *, Kim Hanna and Steve Petteway Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA Summary A large number of clinical documents
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationConducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency
Conducting and reporting a GCP Inspection Gunnar Danielsson Medical Products Agency Preparation for an inspection Inspection plan Create worksheets for the inspection general project specific study specific
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationStephanie Gentilin, CCRA
Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationImplications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials
Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Lisa Marie Saldanha Senior Director & Head Academic Research & Delivery Solutions Real World Insights
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationCommon CSR Template Mapped to ICH E3 and CORE Guidance
Common CSR Template Mapped to ICH E3 and CORE Guidance ICH E3 CORE Common CSR Rationale 1. TITLE PAGE 1. TITLE PAGE TITLE PAGE Per CORE, title page does not 2. SYNOPSIS 2. SYNOPSIS SYNOPSIS require a Heading
More informationTrial Services. The allround trial specialist in cardiology Leading since cardialysis.com
Trial Services The allround trial specialist in cardiology Leading since 1983 cardialysis.com Trial design The key factor in achieving a successful clinical trial is to have a well-prepared, consistent
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationRisk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight
Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationPROTOCOL DRAFTING GUIDE
MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH
More informationRDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust
RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs
More informationEileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA
Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA 1 www.fda.gov WHAT MEDICAL REVIEWERS CAN DO WITH STANDARDIZED DATA AND METADATA RECEIVED IN MODULE 5 Eileen Navarro, MD, FACP OCS/OTS/CDER/FDA
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationClinical Trials & Regulatory
Clinical Trials & Regulatory Infrastructures t MENA Raeda Mustafa, B.Sc.Pharm., MBA, CCRA, CCRC/ Molecule CRO Updates to ICH GCP E6 (R2) and BE Studies 3rd MENA Regulatory Conference on Bioequivalence,
More information1.0 Scope. 2.0 Abbreviations
1.0 Scope This Standard Operating Procedure (SOP) has been written in order to conduct clinical studies according to the International Conference on Harmonisation of Technical Requirements for Registration
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationViews of a Clinical Study Report
Out-of-(CSR)-Body Experiences Tips on Assembling Appendices, Datasets, and CRFs Susan C Sisk, PhD, RAC 1 Views of a Clinical Study Report OR Photos courtesy of Leigh Vaughan and RAPS, 2008 2 Topics Process
More informationClinical Research: A Multifaceted Discipline
Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationDevelopment and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts
Development and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts Namit Ghildyal, Yvette Ng, Craig Tendler, Chris H. Takimoto, Susan Glasser Janssen Research
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationResponsibilities of Investigators for Clinical Trials from Consent to Safety Reporting
Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting Young-Hak Kim, MD, PhD Department of Medicine,, University of Ulsan College of Medicine, Seoul, Korea Responsibilities
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationGUIDELINES FOR CONDUCTING CLINICAL TRIALS.
GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,
More informationDocument Reuse: Theory and Practice
Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here Best Practice: Single Sourcing Creating reusable text and information Requires
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationOFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies
OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationQuality Assurance in Clinical Trials Introduction
Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)
More informationGCP/Clinical Investigation in Japan
GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Development, Review and Amendment: Study Protocol SOP Reference Number: QUB-ADRE-002 Date prepared 28 May 2008 Version Number:
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationPhUSE Paper PP07. EPOCH in Reverse. Ann Croft, LEO Pharma, Hurley, UK
Paper PP07 EPOCH in Reverse Ann Croft, LEO Pharma, Hurley, UK ABSTRACT After supplying test data through the electronic gateway to the FDA, LEO Pharma was informed that the FDA required some updates to
More informationStandard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary
Standard Operating Procedures for Clinical Research Personnel Part 16 Wendy Bohaychuk and Graham Ball GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO Summary This is the 16th in a
More informationSimplifying Clinical Trials
Simplifying Clinical Trials A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. Company Overview : PPCE is an efficient
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationCHAPTER 3 DRUG DEVELOPMENT. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT TO APPROVAL
CHAPTER 3 DRUG DEVELOPMENT indications, which are clearly different from those of drugs, which have already been approved for manufacture and marketing. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT
More informationClinical Trial Basics:
Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial
More informationOFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE
OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationCOMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE
COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationGUIDELINE FOR GOOD CLINICAL PRACTICE TABLE OF CONTENTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE i GUIDELINE FOR GOOD CLINICAL PRACTICE ICH Harmonised Tripartite Guideline Having reached
More informationAn Introduction to Clinical Research and Development
Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is
More informationICH/GCP Guidelines Self-Evaluation Questionnaire
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationAttachment B: A Guideline for Writing a Clinical Protocol for CPRN
Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationDeveloping and Implementing a Comprehensive Clinical QA Audit Program
Developing and Implementing a Comprehensive Clinical QA Audit Program Henry Li 1, *, Susan Hawlk 2, Kim Hanna 1, Gerald Klein 1 and Steve Petteway Jr. 1 1 Talecris Biotherapeutics, 79 T. W. Alexander Drive,
More informationAuthor Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document
MELBOURNE CHILDREN S TRIALS CENTRE (MCTC) Guideline document title: Developing, amending and complying with research protocols Version: 2.0 Author: Melbourne Children s Trials Centre (MCTC) Author Signature:
More informationWelcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site,
Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site, on-site, and central monitoring, and finally, considering
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationImplementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationQUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW???
L.Massad GCP an International Ethical and Scientific quality standard by which clinical trials are designed, implemented and reported so that there is public assurance that the data are credible and the
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationVaccine Prequalification Dossier
Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a
More informationGuidance for Industry
Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationJune 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationHuman Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance
Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify
More information